Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • EGFR
    (5)
  • Epigenetic Reader Domain
    (2)
  • PROTACs
    (2)
  • c-Met/HGFR
    (1)
  • Others
    (1)
TargetMol | Tags By ResearchField
  • Cancer
    (2)
  • Others
    (1)
Filter
Search Result
Results for "

T8634

" in TargetMol Product Catalog.
  • Inhibitors & Agonists
    9
    TargetMol | All_Pathways
  • PROTAC Products
    2
    TargetMol | PROTAC
  • 8-Bromotheophylline
    Bromotheophylline
    T863410381-75-6
    8-Bromotheophylline (Bromotheophylline) is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, 8-Bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome
    • $29
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • CFT8634
    T734252704617-96-7
    CFT8634 is an orally active and selective degrader targeting BRD9, with effects on the proliferation of SMARCB1-deficient cancer cell lines. CFT8634 induces the formation of a ternary complex with BRD9 and E3 ligase, inducing BRD9 ubiquitination and subsequent degradation by the proteasome.
    • $268
    In Stock
    Size
    QTY
  • (S,R)-CFT8634
    T786602704617-95-6
    (S,R)-CFT8634 is a selective and orally active BRD9 protein degrader with potential for researching BRD9-mediated disorders, such as abnormal cellular proliferation [1].
    • $1,370
    8-10 weeks
    Size
    QTY
  • EGFR mutant-IN-2
    T863442770009-06-6
    EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].
    • $1,520
    6-8 weeks
    Size
    QTY
  • EGFR T790M/L858R-IN-4
    T863453032760-34-9
    EGFR T790M/L858R-IN-4, a potent inhibitor of EGFR T790M/L858R with anticancer properties (WO2024064091A1; Example 14) [1].
    • Inquiry Price
    3-6 months
    Size
    QTY
  • EGFR T790M/L858R-IN-5
    T863463032760-70-3
    EGFR T790M/L858R-IN-5 (example 52) functions as a potent EGFR T790M/L858R inhibitor, demonstrating a 92.9% inhibition rate at a concentration of 0.05 μM [1].
    • $1,520
    6-8 weeks
    Size
    QTY
  • EGFR T790M/L858R-IN-6
    T863473032760-71-4
    EGFR T790M/L858R-IN-6 (compound 53), classified as a pyrimidine compound, serves as an effective inhibitor of EGFR T790M/L858R, demonstrating 90.88% inhibition of enzyme activity at a concentration of 0.05 μM [1].
    • Inquiry Price
    3-6 months
    Size
    QTY
  • EGFR T790M/L858R-IN-7
    T863483032760-90-7
    EGFR T790M/L858R-IN-7 (Compound 72), a novel pyrimidine compound, exhibits high efficacy in inhibiting the EGFR T790M and L858R mutations, with a 93% inhibition rate at 0.05 μM. It achieves its inhibitory action by specifically binding to the kinase domain of EGFR, which prevents phosphorylation activity [1].
    • $1,520
    8-10 weeks
    Size
    QTY
  • EGFR/c-Met-IN-2
    T863492761180-01-0
    EGFR/c-Met-IN-2 (Compound H-22) is a dual inhibitor of EGFR/c-Met that arrests the G2/M phase to inhibit cell proliferation and demonstrates antitumor activity [1].
    • $1,820
    10-14 weeks
    Size
    QTY